drugset / Trial / NCT01285635

A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck

NCT01285635

Phase 2 Terminated 35 enrolled University of Michigan Rogel Cancer Center
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will examine the effects of an investigational drug called AT-101 in combination with an FDA approved cancer drug called Docetaxel. It is hoped that AT-101 will help the Docetaxel to have a better effect in slowing or stopping cancer cell growth. This study will help the researchers learn what effects, if any, the combination of AT-101 and Docetaxel has on your cancer. For instance, will the combination cause your tumor(s) to shrink or stop growing? The researchers will also learn about the safety of the combination of AT-101 and Docetaxel. For instance, are there any side effects? If so, what kind of side effects does the combination cause? How severe are the side effects, and how often do they occur?

Timeline

Start
2010-06
Primary completion
2012-12
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AT-101 Small molecule 20 mg
Subject AT-101 Small molecule 40 mg
Subject Docetaxel Small molecule 75 mg/m2